Key takeaways
- Algorithmiq targets quantum advantage on today's noisy gate-based machines rather than waiting for fault tolerance, focusing on life science problems like molecular simulation.
- Getting useful results from NISQ hardware requires combining quantum circuits with classical techniques such as error mitigation and tensor networks, not quantum algorithms alone.
- Life sciences problems like protein folding and drug interactions are chosen because they map naturally onto quantum mechanical systems, unlike more abstract optimization tasks.
- Sabrina gives a concrete timeframe for when she expects quantum advantage to materialize in real applications, based on current hardware and algorithmic progress.
Summary
Sabrina Maniscalco, co-founder and CEO of Algorithmiq, a company that is bringing quantum to life and to life sciences, is interviewed by Yuval Boger. Sabrina and Yuval talk about Algorithmiq’s approach to achieving quantum advantage for life science applications using NISQ-era gate-based machines, her prediction for when quantum advantage will be achieved, the journey from Sicilia to Finland, and much more.
Interested in the transcript? Read it on the Quantum Computing Report site